Ilyas K. Colombowala, MD, FACC, FHRS
Cardiac Electrophysiology · Houston, TX · colombowala.com

Drug

Sotalol

A beta-blocker with class III (IKr-blocking) activity — rate and rhythm control in one molecule. QT and renal function govern its safety, and initiation is usually done on telemetry.

Indication
Maintenance of sinus rhythm in AF/atrial flutter and suppression of ventricular arrhythmias
Typical dose
80–160 mg PO twice daily, adjusted for renal function and QT; initiation/up-titration with telemetry

Why we use it

Sotalol is useful precisely because it does two jobs: it is a beta-blocker and a class III antiarrhythmic. That combination makes it attractive for AF/flutter rhythm control and ventricular arrhythmia suppression (including in ICD patients to reduce shocks) when you want rate control and repolarization prolongation together.

Mechanism

Commercial sotalol is a racemic mix. Both enantiomers block IKr (class III, prolonging repolarization and QT); the l-isomer also provides non-selective beta-blockade (class II). So you get slowed sinus rate and AV conduction plus prolonged refractoriness.

Dosing and renal function

  • Typical 80–160 mg BID, titrated to effect and QT.
  • Renally cleared — dosing interval is extended as CrCl falls, and it is generally avoided below CrCl ~40 mL/min. Always dose to renal function.

Initiation protocol

Because torsades risk is front-loaded, initiation and dose increases are done carefully, usually with continuous telemetry (often inpatient):

  • Baseline QTc, electrolytes, and CrCl.
  • Check QTc 2–4 hours after each dose, near peak effect.
  • Hold / reduce if QTc exceeds ~500 ms (or increases markedly from baseline).
  • Ensure K⁺ and Mg²⁺ are replete before and during initiation.

Monitoring and cautions

  • Ongoing ECG (QTc), renal function, and electrolytes.
  • Contraindicated / cautioned: congenital or acquired long QT, significant renal impairment, decompensated heart failure, marked bradycardia or high-grade AV block without a pacemaker, and asthma/reactive airway disease (non-selective beta-blockade).
  • Watch for the usual beta-blocker effects — fatigue, blunted exercise tolerance, masked hypoglycemia.

Interactions

  • Additive QT prolongation with class III/IA agents, many antiemetics, macrolides, and antifungals.
  • Additive bradycardia/AV block with other beta-blockers, non-DHP CCBs, digoxin.
  • Potassium-wasting diuretics raise torsades risk by lowering K⁺/Mg²⁺.

Common pitfalls

  • Dosing on weight or symptoms instead of renal function and QT.
  • Up-titrating without telemetry and a peak-effect QTc check.
  • Starting sotalol in a patient with unrecognized CKD or hypokalemia.
  • Forgetting that it is also a real beta-blocker — abrupt withdrawal can cause rebound.

Last reviewed by Dr. Colombowala on May 27, 2026.

Clinical-reference content, not medical advice. This page is written for EP staff and does not create a doctor-patient relationship. It does not replace institutional policy, current device manuals, or attending direction during a case. See the full disclaimer.

© 2026 Ilyas K. Colombowala, MD. All rights reserved. Reproduction, redistribution, or republication of this content in any form without written permission is prohibited.

Source: